β-Carbonic Anhydrase as a Target for Eradication of 
Mycobacterium tuberculosis

Noor HN*
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kufa, Najaf, Iraq

*Corresponding author: Noor H Naser, PhD, Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kufa, Najaf, Iraq, Email: noorh.naser@uokufa.edu.iq

Abstract
Infectious diseases are among the most danger, and deadly afflictions that human societies suffering from there. One of the common re-emerged infectious diseases is tuberculosis (TB). The causative pathogen for this disease has developed several methods to resist the ordinary therapy, which are usually acting through inhibition of nucleic acids. Therefore, new researches focused on development of tuberculosis treatment, through discovery of novel targets, on which new synthesized drugs will act. One of these targets that can be utilized for eradication of tuberculosis is carbonic anhydrase enzyme.

Keywords: β-Carbonic Anhydrase; Mycobacterium tuberculosis; Infectious diseases

Introduction
Tuberculosis is one of the ancient infectious disease which has been re-emerged, long after the medical establishment was considered it to be declined [1]. The re-emergence is particularly due to the development of resistance to the ordinary therapy [2]. The appearance of multi-drug resistance tuberculosis (MDR-TB), and extensively drug resistance tuberculosis (XDR-TB), made a great obstacle for controlling of this infectious disease [3].

Tuberculosis is a global airborne disease, which caused by gram positive bacterium Mycobacterium tuberculosis (Mtb) [4]. This bacteria is non-motile, non-spore forming, aerobic rods, its cell wall is highly hydrophobic, due to richness with different types of lipids [5]. The ordinary anti-tuberculosis drugs can be classified into; First line drugs; include Isoniazide (INH), Rifampicin, Ethambutol, Pyrazinamide, and Streptomycin [6]. Second line drugs; include Amikacin, Capreomycin, Cycloserine, Thiacetazone, Ethionamide, Para-aminosalicylic acid, and quinolones as ciprofloxacin.

MDR-TB, mean the simultaneous resistance to one or more of the five first line drugs [3], while the XDR-TB, mean the resistance to at least Isoniazid and Rifampicin in addition to one of quinolones, and at least one of the injectable second line drugs as Amikacin [7].

The resistance situation demonstrates a demand for development of novel approaches for TB treatment. A potential method to overcome the resistance problem is to design, and synthesize novel and innovative chemical agents that act on novel targets, through different mechanisms of action.
Carbonic Anhydrase as New Target for Tb Treatment

Carbonic anhydrase is a metallo enzyme, which catalyze the hydration of carbon dioxide to bicarbonate, by that control the pH homeostasis inside the cell [8]. This enzyme is present in both eukaryotes, and prokaryotes, and encoded by five gene families; α (in vertebrates), β (in bacteria and fungi), γ (archaea), δ and ζ (in marine diatoms) [9]. Mycobacterium tuberculosis contains three β-carbonic anhydrase (CA) genes in its genome, that encoding for three proteins, named mtCA 1, mtCA 2 and a third enzyme, mtCA 3 [10, 11].

Catalytic Mechanism of Carbonic Anhydrase

In all enzyme classes, a metal hydroxide species (L₃−M²⁺−OH) of the enzyme is the catalytically active species, acting as a strong nucleophile (at neutral pH) on the CO₂ molecule bound in a hydrophobic pocket nearby. This metal hydroxide species is generated from water coordinated to the metal ion, which is found at the bottom of the active site cavity "funnel-shaped active site pocket". The active center normally comprises M (II) ions in tetrahedral geometry, with three protein ligands (L) in addition to the water molecule/hydroxide ion, but Zn (II) and Co (II) were also observed in trigonal bipyramidal or octahedral coordination geometries, at least in γ-CAs [8]. However, all appear to share the same overall catalytic mechanism composed of two independent stages, shown in Equations 1 and 2, an example of a ping-pong mechanism. In the hydration direction, the first stage is the conversion of CO₂ into bicarbonate via a nucleophilic attack on CO₂ by the reactive zinc-bound hydroxide. The resultant bicarbonate is then displaced from the zinc by a water molecule.

The second stage is the transfer of a proton from the zinc bound water to bulk solvent to regenerate the zinc-bound hydroxide. Here B is a proton acceptor in solution or a residue of the enzyme itself [12].

![Figure 1: Active site and mechanism of action of carbonic anhydrases [8].](image-url)
dyad), makes a salt bridge with the Asp coordinated to Zn (II), liberating the fourth Zn (II) coordination position, which is then occupied by an incoming water molecule/hydroxide ion, as shown in the structures of two β-CAs from Mycobacterium tuberculosis, encoded by Rv1284 and Rv3588c genes [10].

Figure 2: β-carbonic anhydrase active site obtained from Mycobacterium tuberculosis [13].

The cavity is partitioned into two very different environments. On one side of the zinc, deep within the active site, lies a cluster of hydrophobic amino acids (namely Val, Leu, Thr, and Trp.), whereas on the other side of the zinc, leading out of the active site to the bulk solvent, the surface is lined with hydrophilic amino acids (namely Tyr, Asn, His, Thr-199-O_1, and Thr-200-O_1) [8, 12].

**Carbonic Anhydrase Inhibitors**

There are three main classes of inhibitors [14].

1. The pharmacologically relevant unsubstituted sulfonamides and their isosteres (sulfamates, sulfamides, ureates and hydroxamates).
2. The simple inorganic anions (metal complexing anions).
3. Coumarins.

These inhibitors bind to the Zn$^{2+}$ ion of the enzyme either by substituting the non-protein zinc ligand to generate a tetrahedral adduct, or by addition to the metal coordination sphere to generate trigonal-bipyramidal species [15]. As shown in the following equations [8];

\[
\begin{align*}
\text{E-Zn}^{2+}-\text{OH}_2 + l & \rightarrow \text{E-Zn}^{2+}-l + \text{H}_2\text{O} \quad \text{(Substitution reaction)} \\
\text{E-Zn}^{2+}-\text{OH}_2 + l & \rightarrow \text{E-Zn}^{2+}-\text{OH}_2 (l) \quad \text{(Addition reaction)}
\end{align*}
\]

The unsubstituted sulfonamides and their bioisosteres, which are the most important CAIs, bind in the tetrahedral geometry of the Zn$^{2+}$ ion of the enzyme (Figure 3A), in deprotonated state, with the nitrogen atom of the sulfonamide moiety coordinated to Zn$^{2+}$ and an extended network of hydrogen bonds involving residues Thr and Glu, also participating to the anchoring of the inhibitor molecule to the metal ion. While the anions add to the metal coordination sphere, generating trigonal-bipyramidal specie, such as the thiocyanate adduct shown in (Figure 3B) [16].

Figure 3: Binding of inhibitors with carbonic anhydrase active site [8].

The aromatic/heteroaromatic part of the inhibitor (R) viz; sulfonamide/sulfamate/sulfamide interact with the hydrophilic and hydrophobic residues of carbonic anhydrase. In deprotonated state as SO$_2$NH it is coordinated to Zn$^{2+}$ of the enzyme, and it is −NH$^-$ moiety participate in the hydrogen bond with the oxygen of Thr., which in turn is engaged in another hydrogen bond to the carboxylate group of Glu. One of the oxygen atoms of the −SO$_2$NH$^-$ moiety also participates in a hydrogen bond with the backbone −N$^-$ moiety of Thr [17].

A general pharmacophore (Figure 4), for the compounds acting as carbonic anhydrase inhibitors has been reported by Thiry et al. from the analysis of the CA active site and from the structure of the inhibitors described in the literature. This pharmacophore includes the structural elements that are required to be present in the compounds in order to act as CA inhibitors. This includes the presence of a sulfonamide moiety which coordinates with the zinc ion of the active site of the CA and the sulfonamide is attached to a scaffold which is usually a benzene ring. The side chain might possess a hydrophilic link able to interact with the hydrophilic part of the active site and a hydrophobic moiety which can interact with the hydrophobic part of the CA active site.
It was determined that is the nature of the R group that greatly influences the binding to the enzyme. Thus, the nature of the R moiety is the determining factor in controlling the inhibitory power, probably due to flexibility of the linker and the possibility of the R group to orientate in different sub-pockets of the active site cavity of these enzymes. It may be observed that the elongation of the inhibitor molecule, by means of a sulfanilyl moiety, such as in compounds 1, 2, and 3 leads to a roughly 10 times increase of the inhibitory power of the corresponding sulfonamide against mtCA 2, which may be an important hint for drug design purposes [18,19].

**Conclusion**

The development of resistance against most of the ordinary therapeutic agents of infectious diseases represents a pressing problem, and required the development of the clinical therapeutic compounds to be effective against previously unexploited targets. Many carbonic anhydrases isolated from organisms open a new therapeutic target, such as α-CA from *Plasmodium falciparum* and *Helicobacter pylori*, and β-CA from *Mycobacterium tuberculosis* and *Candida albicans* etc. Researchers are being carried out for developing specific inhibitors targeting these enzymes that would lead to conceptually novel therapies.

**References**

1. David AL, Robin R, Alastair DB, David JH, Stewart Fleming (2008) MUIR’S Textbook of pathology 14th (Edn) Edward Arnold (Publishers) Ltd., India, pp. 508-545.
2. Mohammad Asif (2012) Recent Efforts for the Development of Antitubercular Drug Containing Diazin Ring. Medicinal chemistry, an open access journal 2(7): 151-167.
3. George Tegos and Eleftherios Mylonakis (2012) Antimicrobial drug discovery, Emerging Strategies: Advances in Molecular and Cellular Microbiology. CPI Group (UK) Ltd, UK, 7-25.
4. Simone W, Georgia K, Manfred SW (2007) The Three-Dimensional Structure of *N*-Succinyldiaminopimelate Aminotransferase from *Mycobacterium tuberculosis*. Journal of Molecular Biology 367: 825–838.
5. Patric RM, Ken SR, Michael A (2013) Faller: Medical Microbiology 7th (Edn) Elsevier Inc, China, pp. 235-247.
6. S D Seth, Vimlesh Seth (2009) Text Book of Pharmacology 3rd (Edn) Rakmo Printers Pvt. Ltd, India, pp. 77, X.74-X.84.
7. Kamal A, Azeeza S, Malik MS, Shaik AA, Rao MV (2008) Efforts towards the Development of New Antitubercular Agents: Potential for Thiolactomycin Based Compounds. Journal of Pharm Pharmceut Sci 11: 56-80.
8. Fabio Pacchiano, Andrea Scozzafava, and Andrea Goti (2010) Design, synthesis and biological evaluation of novel carbonic anhydrase inhibitors against mammalian, bacterial and fungal isoforms. Faculty of SFMN, Department of Chemistry, Florence University, Italy.
9. Lina Baranauskienė, Daumantas Matulis (2012) Intrinsic Thermodynamics of Ethoxzolamide Inhibitor Binding to Human Carbonic Anhydrate XIII. BMC Biophysics 5:12.
10. Covarrubias AS, Bergfors T, Jones TA, Hogbom M (2005) Structural Mechanics of the pH-dependent Activity of β-Carbonic Anhydrase from Mycobacterium tuberculosis. The Journal of Biological Chemistry 281(8): 4993-4999.

11. Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Innocenti A, et al. (2009) Carbonic Anhydrase Inhibitors. Cloning, Characterization, and Inhibition Studies of A new β -Carbonic Anhydrase from Mycobacterium tuberculosis. Journal of Medicinal Chemistry 52: 3116.

12. Domsic JF, Avvaru BS, Kim CU, Gruner SM, Agbandje Mc, et al. (2008) Entrapment of Carbon Dioxide in the Active Site of Carbonic Anhydrase II. Journal of Biological Chemistry 283(45): 30766-30771.

13. Francesca V, Simona MM, Giuseppina DS, Alessio I, Andrea S, et al. (2010) Inhibition of the R1 Fragment of the Cadmium-Containing ζ-class Carbonic Anhydrase from the Diatom Thalassiosiraweissflogii with Anions. Bioorganic & Medicinal Chemistry Letters 20: 4745-4748.

14. Vincenzo A, Simona MM, Emanuela T, Carlo P, Claudiu TS, et al. (2010) The First Example of A significant Active Site Conformational Rearrangement in A Carbonic Anhydrase-Inhibitor Adduct: The Carbonic Anhydrase I–Topiramate Complex. Organic & Biomolecular Chemistry 8: 3528-3533.

15. Robert RC (2008) Biological Inorganic Chemistry an Introduction 1st (Edn). Elsevier Inc. Italy pp. 197-210.

16. Blessy P, Vineet S, Surendra K, Meena T (2010) Structural Optimization of New Class of Selective Carbonic Anhydrase Inhibitors: QSAR Approach. Indian Journal of Chemistry 49B: 224-233.

17. Alaa HJ, Jawad KS, Ahmed A, Mustafa MA (2012) Synthesis, Characterization, and Evaluation of Biological Activity of Some Heterocyclic Compounds Containing 1, 2, 4-Triazole Ring. International Journal of Research in Pharmacy and Chemistry 2(4): 1109-1123.

18. Carta F, Maresca A, Covarrubias AS, Mowbray SL, Jones TA, et al. (2009) Carbonic Anhydrase Inhibitors. Characterization and Inhibition Studies of the Most Active β-carbonic Anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorganic & Medicinal Chemistry Letters 19: 6649–6654.

19. Noor HN, Mohammed HM (2015) Design, Synthesis, and Anti-tuberculosis Evaluation of ciprofloxacin-sulfonamide conjugates Utilizing Hybridization Approach. College of pharmacy, Baghdad University, Iraq.